WallStSmart
ZTS

Zoetis Inc

NYSE: ZTS · HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC

$114.97
+1.00% today

Updated 2026-04-30

Market cap
$48.05B
P/E ratio
18.91
P/S ratio
5.08x
EPS (TTM)
$6.02
Dividend yield
1.71%
52W range
$113 – $170
Volume
3.8M
OverviewPrice TargetsFinancialsValuationInsidersEarnings

Zoetis Inc (ZTS) Financial Forecast & Price Target 2030

Research-backed projections from analyst consensus, management guidance, and sector analysis.

Price target summary

Current
$114.97
Consensus
$156.20
+35.86%
2030 Target
$330.23
+187.23%
DCF
$160.64
+19.90% MoS
11 analysts:
2 Buy7 Hold0 Sell

Management guidance

Zoetis provided FY2026 guidance on Feb 12, 2026 earnings call. Company forecasts revenue growth of approximately 5-6% for 2026 ($10.0B revenue), with continued mid-single-digit growth trajectory through 2027 ($10.49B). Management emphasized steady companion animal demand and integration of recent acquisitions (Neogen genomics for $160M) as growth drivers, though facing near-term headwinds in Librela (osteoarthritis drug) demand and routine vet visit declines.

Sources: Management guidance, analyst consensus, sector analysishigh confidence

Revenue & price projection

Actual revenue Projected revenue Base case Bull to bear range
Bull case (2030)
$554.32
$12.3B Rev × 20x P/S
Base case (2030)
$330.23
$12.3B Rev × 12x P/S
Bear case (2030)
$224.09
$12.3B Rev × 8x P/S

Financial forecast — research-backed

Metric2023202420252026 (E)2027 (E)2028 (E)2029 (E)2030 (E)
Revenue$8.5B$9.3B$9.5B$10.0B$10.5B$11.1B$11.7B$12.3B
Revenue growth—8.3%2.3%5.7%4.9%5.3%5.7%5.6%
EPS$5.32$5.92$6.27$7.08$7.62$8.15$8.68$9.24
P/S ratio———12.0x12.0x12.0x12.0x12.0x
Implied price———$271.26$283.06$306.64$318.44$330.23

Catalysts & risks

Growth catalysts
+ Neogen animal genomics acquisition integration driving precision animal health revenue expansion
+ Companion animal franchise stabilization and premium pet care spending resilience despite vet visit declines
+ Livestock and poultry segment recovery and international market penetration acceleration
+ Pipeline innovations in vaccines, medicated feed additives, and precision diagnostics
+ Capital allocation through share buybacks and dividend growth supporting EPS accretion
Key risks
- Librela (osteoarthritis) competitive pressure and demand normalization after blockbuster growth phase
- Routine veterinary visit decline (16th consecutive quarter down) constraining core pharmaceutical sales
- Analyst sentiment deterioration—ratings shifted from Buy to Hold; BofA and Piper Sandler downgraded on growth concerns
- Integration execution risk on Neogen acquisition and ability to monetize precision genomics platform
- Margin compression from higher R&D spend on innovation pipeline and acquisition amortization

Methodology

Zoetis Inc's forward estimates are derived from AI-powered research synthesis combining analyst consensus from 11 Wall Street analysts, management guidance from the latest earnings call, and sector growth forecasts from industry research. Revenue and EPS projections use analyst consensus where available and conservative extrapolation with growth deceleration for outer years. Price targets are calculated using a tiered Price-to-Sales (P/S) methodology, where the P/S multiple is determined by the projected revenue growth rate.

WallStSmart proprietary research model · Not financial advice · Past performance is not indicative of future results · Last researched: April 7, 2026.